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Background: Illicit drug use is a well-established risk factor for morbidity and mortality. However, few studies have
examined the impact of different drug use patterns on mortality among polysubstance using populations. This
study aimed to identify drug-specific patterns of mortality among a cohort of polysubstance using persons who
inject drugs (PWIDs).
Methods: PWIDs in Vancouver, Canada were prospectively followed between May 1996 and December 2011.
Participants were linked to the provincial vital statistics database to ascertain mortality rates and causes of death.
We used multivariate Cox proportional hazards regression to investigate the relationships between drug use
patterns (daily alcohol use, heroin injection and non-injection use, cocaine injection, amphetamine injection and
non-injection use, crack smoking and speedball injecting) and time to all-cause mortality.
Results: 2330 individuals were followed for a median of 61 months (inter-quartile range: 33 – 112). In total, 466
(19.1%) individuals died for an incidence density of 3.1 (95% confidence interval [CI]: 2.8 – 3.4) deaths per 100
person-years. In multivariate analyses, after adjusting for HIV infection and other potential confounders, only daily
cocaine injection remained independently associated with all-cause mortality (adjusted hazard ratio [AHR] = 1.36,
95% CI: 1.06 – 1.76).
Conclusions: Although heroin injecting is traditionally viewed as carrying the highest risk of mortality, in this
setting, only daily cocaine injecting was associated with all-cause mortality. These findings highlight the urgent
need to identify novel treatments and harm reduction strategies for cocaine injectors.
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Illicit drug use has been well established as a risk factor
for adverse health outcomes including premature mor-
tality [1-6]. Previous studies have indicated that fatal
overdose accounts for a majority of deaths in illicit drug-
using populations, particularly among persons who in-
ject drugs (PWIDs) [3-5,7,8]. Much of the existing litera-
ture has highlighted opioid use associated with fatal
overdose [1,7,9,10]. One meta-analysis found that illicit* Correspondence: uhri-ew@cfenet.ubc.ca
1British Columbia Centre for Excellence in HIV/AIDS, St. Paul’s Hospital,
608 - 1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada
2Department of Medicine, University of British Columbia, 317-2194 Health
Sciences Mall, Vancouver, BC V6T 1Z3, Canada
© 2014 Hayden et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.opiate users have a mortality rate thirteen times that of
the general population [1]. An increased mortality rate
has also been demonstrated among users of other sub-
stances, including cocaine and amphetamines [4,6,11,12].
Earlier studies of mortality among PWIDs have often
been limited by the fact that they were restricted to
cross-sectional examinations of toxicology reports
among deceased individuals where important potential
confounders, such as human immunodeficiency virus
(HIV) infection or other socio-demographic comorbidi-
ties, like homelessness, were difficult to control for
[2,7,13,14]. While longstanding prospective cohort stud-
ies of PWIDs exist in a number of regions, some of
which have adjusted for potential confounders, manyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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of specific drugs are primarily used (e.g. primarily heroin
or cocaine users) [7,10,11,15-17].
The Downtown Eastside of Vancouver (DTES), Canada
is well known for its concentration of poly-substance use,
high prevalence of hepatitis C virus (HCV) and HIV infec-
tion and high rates of homelessness [18,19]. The DTES is
among the most impoverished neighborhoods in Canada
with an estimated 5000 PWIDs residing in the area
[18,19]. Various patterns of drug use in this population
have been described in previous studies including high
rates of cocaine injecting [20], crack cocaine smoking
[21], amphetamine injecting [22] and heroin injecting
[23]. Accordingly, it provides an excellent environment
to examine the contribution of specific drug use patterns
on mortality. Therefore, the present study aimed to iden-
tify drug specific patterns of mortality among a cohort of
polysubstance using PWIDs in Vancouver.
Methods
The Vancouver Injection Drug Users Study (VIDUS)
and AIDS Care Cohort to Evaluate Access to Survival
Services (ACCESS) are open prospective cohorts of drug
users in Vancouver. The recruitment and follow-up pro-
cedures for the two studies are identical to allow for
analyses of merged data, with the only differences being
that HIV-positive individuals are followed in ACCESS
whereas HIV-negative individuals are followed in VIDUS
and that ACCESS includes non-injecting drug users. In
both studies the primary modes of enrollment were self-
referral, word of mouth, and street outreach. Detailed
sampling and recruitment procedures for these two
cohorts have been described elsewhere [20,24,25].
To be eligible, participants were 18 years of age or
older, had used illicit drugs other than cannabinoids in
the previous month and resided in the greater Vancouver
region. All participants provided written informed con-
sent. Participants were given a stipend ($20 CDN) at each
study visit for their time and transportation. The study
was approved by the University of British Columbia/
Providence Healthcare Research Ethics Board.
At baseline and semianually thereafter, participants
completed an interviewer-administered questionnaire
that elicited a range of data, including demographic
characteristics, injection and non-injection drug use, and
sexual risk behaviors. In addition, venous blood samples
were drawn at each visit and tested for HIV and HCV
antibodies. All participants had private interviews and
were offered both pre- and post-test counseling with
trained nurses. Referral for free healthcare was provided
to those who tested HIV positive and these individuals
were subsequently followed in ACCESS.
We ascertained all-cause mortality rates and under-
lying causes of death among participants through aconfidential record linkage with the British Columbia
Vital Statistics Agency and through ongoing follow-up
with contacts provided by participants. The Vital Statistics
database recorded causes of death according to the Inter-
national Classification of Diseases (ICD), 10th edition.
The present study included PWIDs who were re-
cruited and completed at least one follow up visit be-
tween May 1996 and December 2011. To avoid potential
bias relating to long durations between the last study
visit where behavioural information was assessed and
the date of death (i.e. loss to regular follow up), individ-
uals who were identified as deceased more than
12 months after the the last follow up visit were cen-
sored on the date of the last follow up.
The primary endpoint in this analysis was all-cause
mortality. The primary explanatory variables of interest
included a number of substance use behaviors in the
previous six months, including at least daily alcohol use,
at least daily cocaine injection, at least daily heroin injec-
tion and non-injection use, at least daily amphetamine
injection and non-injection use, at least daily crack
cocaine smoking and at least daily speedball injecting
(a mixture of cocaine and heroin). Additionally, we
examined risk associated with non-daily heroin and
amphetamine use defined as any report of use in the last
six months. Potential confounders that were considered
included: age (per 10 years older); gender (male vs. female),
time since first injection (per 10 years longer); ethnicity
(Caucasian vs. others); HIV serostatus (positive vs. nega-
tive); and unstable housing in the previous six months. As
previously, unstable housing was defined as living in one
of the DTES’ single room occupancy hotels, shelters or
other transitional housing, or living on the street [26,27].
As an initial analysis, we used the Chi-square test and
Wilcoxon rank sum test to compare the baseline charac-
teristics of the included and excluded individuals, and
those who did and did not report daily cocaine injection in
the previous six months among the included sample based
on an interest in the role of cocaine injecting on mortality.
All-cause mortality rate and 95% confidence interval [CI]
were calculated using the Poisson distribution.
Next, we used bivariate and multivariate Cox propor-
tional hazards regression to examine the relationship be-
tween substance use patterns and time to death. All
behavioral variables including substance use patterns,
unstable housing and HIV serostatus were treated as
time-varying variables. The multivariate model was fit
using an a priori defined protocol whereby all illicit drug
use variables were entered into the multivariate model.
Variables found to be significantly associated with time to
all-cause mortality in bivariate analyses at p <0.10 were en-
tered into the multivariate model as potential confounders.
We also conducted a sub-analysis where we restricted
the dependent variable to accidental poisonings (ICD-10:
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ically examine if drug use patterns were associated with
accidental death. All statistical analyses were performed
using SAS software version 9.3 (SAS, Cary, NC). All
p-values were two-sided.
Results
A total of 2597 individuals were recruited between May
1996 and December 2011, among whom 267 were ex-
cluded as a result of no follow-up information. In com-
paring the study sample to those that were excluded, the
excluded sample was younger, less likely to be HIV posi-
tive and was less likely to inject cocaine and speed ball
(all p <0.05).
The remaining 2330 (89.7%) were followed for a me-
dian of 61 months (inter-quartile range [IQR]: 33 – 112).
Table 1 shows the baseline characteristics of the study
sample. As shown, at baseline, 1550 (66.5%) were men,
640 (27.5%) were HIV positive, and 1424 (61.1%) were
Caucasian. The median age was 37.3 years (IQR: 29.4 –
43.7), and the median time since first injection was
14.4 years (IQR: 6.2 – 24.2). At baseline, 550 (23.6%) of
the study sample consumed alcohol daily in the previous
six months, 901 (38.7%) injected heroin daily, 97 (4.2%)
smoked heroin daily, 1588 (68.2%) injected cocaine daily,
51 (2.2%) injected amphetamines daily, 7 (0.3%) smoked
amphetamines daily, 560 (24.0%) smoked crack cocaine
daily, and. 288 (12.4%) injected speedball daily.
Compared to non-daily cocaine injectors, those who
reported daily cocaine injection at baseline were more
likely to be younger (odds ratio [OR] = 0.76, 95% CI:
0.69 – 0.83), to reside in unstable housing (OR = 1.62,
95% CI: 1.32 – 1.99), and to have less time since first in-
jection (OR = 0.91, 95% CI: 0.84 – 0.99). They were less
likely to be male (OR = 0.70, 95% CI: 0.58 – 0.84) and
report Caucasian ethnicity (OR = 0.77, 95% CI: 0.64 –
0.92). In terms of drug use patterns, daily cocaine injec-
tion was significantly and positively associated with daily
heroin injection (OR = 1.68, 95% CI: 1.40 – 2.00) and
speedball injection (OR = 9.01, 95% CI 6.77 – 12.00),
and negatively associated with daily amphetamine injec-
tion (OR = 0.34, 95% CI: 0.15 – 0.76), and daily crack
smoking (OR = 0.65, 95% CI: 0.52 – 0.80).
In total, 466 (19.1%) individuals died for an incidence
density of 3.1 (95% CI: 2.8 – 3.4) deaths per 100 person-
years. The primary underlying causes of death included
accidental poisonings (22.6%) and HIV disease (18.5%).
The remaining 100 classified categories including assault
(2.3%) and lung malignancy (2.4%) are varied and each
individually contributed less than 5%, with most contrib-
uting less than 1% to all-cause mortality.
Table 2 shows results of the bivariate and multivariate
Cox regression analyses of all-cause mortality. In the bi-
variate analysis, daily cocaine injection was significantlyand positively associated with time to all-cause mortality
with a hazard ratio (HR) of 1.41 (95% CI: 1.12 – 1.78)
whereas daily heroin injection was significantly and
negatively associated with the ouctome with a HR of
0.75 (95% CI: 0.60 – 0.95). Daily alcohol use (HR = 0.98,
95% CI: 0.77 – 1.25), daily heroin non-injection use
(HR = 1.12, 95% CI: 0.51 – 2.44), amphetamine injection
(HR = 0.39, 95% CI: 0.10 – 1.54) and non-injection use
(HR = 1.13, 95% CI: 0.29 – 4.50), daily crack cocaine
smoking (HR = 0.91, 95% CI: 0.74 – 1.12) and daily
speedball injection (HR = 1.02, 95% CI: 0.69 – 1.52) were
not significantly associated with time to all-cause mortal-
ity. A bivariate analysis of non-daily heroin use (HR =
0.99, 95% CI: 0.72 -1.37) and amphetamine (HR = 0.47,
95% CI: 0.23 – 1.02) use, which was not included in the
tables showed no significant association with mortality.
In the multivariate analysis, after adjustment for po-
tential confounders including HIV serostatus, age and
unstable housing, daily cocaine injection remained inde-
pendently and positively associated with time to all-
cause death (adjusted hazard ratio [AHR] = 1.36, 95% CI:
1.06 – 1.76) whereas the remaining substance use vari-
ables were not significantly associated with the outcome.
The sub-analysis whereby the dependent variable was
restricted to accidental mortality showed that none of
the substance use variables was significantly associated
with accidental mortality. The only variable where there
was a trend towards an association with accidental mor-
tality was daily crack cocaine injecting, though this was
not statistically significant (AHR = 1.36, 95% CI: 0.91–
2.10). Full data are available from the corresponding
author.
Discussion
In the present study, we found that daily cocaine injec-
tion was independently associated with all-cause mortal-
ity among PWIDs in Vancouver, after adjusting for
potential confounders including age, unstable housing
and HIV serostatus. These variables are known risk fac-
tors for mortality and were included in the analysis in
order to adjust for their potential confounding effects
[8]. The most common causes of death included acci-
dental poisonings and HIV disease. We did not observe
an independent mortality risk associated with daily alco-
hol use, daily heroin injection or non-injection use, daily
amphetamine injection or non-injection use, daily crack
cocaine smoking and daily speedball injecting.
Our findings that daily cocaine injection was the only
drug use behaviour independently associated with mor-
tality were somewhat unique in the context of previous
literature indicating a significant mortality risk associ-
ated with heroin injection most commonly due to fatal
overdose [5]. Heroin use has been shown to carry the
highest mortality risk amongst illicit drugs in some




Yes (%) No (%)
Odds ratio (95% CI) p value
(n = 2330) (n = 1588) (n = 728)
HIV serostatus
Positive 640 (27.5) 212 (29.1) 426 (26.8) 1.12 (0.92 – 1.36) 0.247
Negative 1688 (72.5) 515 (70.7) 1161 (73.1)
Gender
Male 1550 (66.5) 444 (61.0) 1098 (69.1) 0.70 (0.58 – 0.84) <0.001
Female 780 (33.5) 284 (39.0) 490 (30.9)
Ethnicity
Caucasian 1424 (61.1) 413 (56.7) 1001 (63.0) 0.77 (0.64 – 0.92) 0.004
Other 906 (38.9) 315 (43.3) 587 (37.0)
Unstable housing*
Yes 1637 (70.3) 556 (76.4) 1072 (67.5) 1.62 (1.32 – 1.99) <0.001
No 677 (29.1) 163 (22.4) 509 (32.1)
Median age (IQR)
Per 10 year older 37.3 (14.3) 35.3 (13.4) 38.4 (14.1) 0.76 (0.69 – 0.83) <0.001
Median time since first injection (IQR)
Per 10 year longer 14.4 (18.0) 14.1 (16.3) 14.6 (18.8) 0.91 (0.84 – 0.99) 0.033
Daily alcohol use*
Yes 550 (23.6) 179 (24.6) 368 (23.2) 1.10 (0.88 – 1.33) 0.450
No 1775 (76.2) 547 (75.1) 1217 (76.6)
Daily heroin injection*
Yes 901 (38.7) 345 (47.4) 555 (35.0) 1.68 (1.40 – 2.00) <0.001
No 1424 (61.1) 383 (52.6) 1033 (65.1)
Daily heroin (non-injection)*
Yes 97 (4.2) 30 (4.1) 66 (4.2) 0.99 (0.64 – 1.54) 0.969
No 2230 (95.7) 697 (95.7) 1520 (95.7)
Daily amphetamine injection*
Yes 51 (2.2) 7 (1.0) 44 (2.8) 0.34 (0.15 – 0.76) 0.006
No 2274 (97.6) 721 (99.0) 1542 (97.1)
Daily amphetamine (non-injection)*
Yes 7 (0.3) 1 (0.1) 6 (0.4) 0.36 (0.04 – 3.02) 0.445†
2322 (99.7) 727 (99.9) 1581 (99.6)
Daily crack cocaine smoking*
Yes 560 (24.0) 137 (18.8) 420 (26.5) 0.65 (0.52 – 0.80) <0.001
No 1767 (75.8) 589 (80.9) 1167 (73.5)
Daily speedball injection*
Yes 288 (12.4) 216 (29.7) 71 (4.5) 9.01 (6.77 – 12.00) <0.001
No 2038 (87.5) 512 (70.3) 1516 (95.5)
*Refers to activities in the six months prior to interview. IQR = Interquartile range. †Fisher’s Exact Test.
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thought to carry mortality risk due to diminished toler-
ance to respiratory depression effects with sporadic useleading to increased of accidental overdose [30]. How-
ever, our analysis showed no significant increase in mor-
tality risk in both daily and non-daily heroin users.
Table 2 Univariate and multivariate Cox proportional hazard regression analyses of the time to all-cause death among
people who inject drugs in Vancouver, Canada (n = 2330)
Unadjusted hazard ratio (HR) Adjusted† hazard ratio (AHR)
Variable HR (95% CI) p-value AHR (95% CI) p-value
Daily alcohol use* 0.98 0.77 – 1.25 0.854 1.00 0.78 – 1.28 0.979
Daily heroin injection* 0.75 0.60 – 0.95 0.018 0.92 0.71 – 1.19 0.502
Daily heroin (non-injection)* 1.12 0.51 – 2.44 0.779 1.44 0.68 – 3.07 0.340
Daily cocaine injection* 1.41 1.12 – 1.78 0.003 1.36 1.06 – 1.76 0.017
Daily amphetamine injection* 0.39 0.10 – 1.54 0.177 0.41 0.10 – 1.72 0.224
Daily amphetamine (non-injection)* 1.13 0.29 – 4.50 0.859 0.94 0.13 – 6.88 0.949
Daily crack cocaine smoking* 0.91 0.74 – 1.12 0.358 0.83 0.67 – 1.04 0.099
Daily speedball injectionn 1.02 0.69 – 1.52 0.917 0.98 0.62 – 1.56 0.944
*Refers to activities in the six months prior to interview. †Model was adjusted for HIV serostatus, age, and unstable housing.
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tween these previous studies and our study findings are
not entirely clear, a contributing factor may be related to
frequency of drug injecting, which was not accounted
for in the previous studies [4,8]. Due to the short half life
of cocaine, injectors will often use greater than 20 times
in a day, predisposing them to increased risk of infec-
tion/bacteremia and other associated negative health ef-
fects, while local heroin injectors typically inject only 2
to 4 times per day [20]. Rates of injecting may increase
risk of bacterial infection, needle sharing and other po-
tential risks of mortality (e.g. air embolus, cellulitis, etc.)
[12,20,28].
We also found a differential risk of mortality between
cocaine injectors and crack smokers. Some cohort stud-
ies have demonstrated an independent mortality risk as-
sociated with cocaine use [4,12] in addition to significant
morbidity associated with the use of this substance, in-
cluding cardiovascular, psychiatric, neurologic disorders
and unintentional injuries [16]. Much of the mortality
data on cocaine use however does not distinguish be-
tween injecting and smoking crack cocaine [16,17,28].
Furthermore, the majority of these studies present data
in standardized mortality ratios, which allow for a com-
parison with the general population but not between
sub-groups of cocaine-using populations, as performed
in the present study. Though both cocaine injection
and crack smoking have been shown to be associated
with HIV infection in this setting [20,31], our multivari-
ate analyses suggest that daily cocaine injectors appear
to be at an elevated risk of mortality due to the risks
associated with injection practices other than HIV
infection.
Harm reduction strategies, including a supervised
injecting facility, in Vancouver’s DTES have been shown
to be successful at attracting cocaine injectors, reducing
rates of fatal overdose [32,33] and reducing syringesharing and HIV risk behavior [34,35] among the local
PWID population. It is noteworthy that both cocaine
and heroin injectors utilize this unique program, [35]
which is widely accessible for extended hours. It also
connects PWIDs to addiction services, contributing
to quicker entry into detoxification programs [36]
and leading to increased likelihood of stopping drug
injecting [37].
The findings of this study highlight a need to further
identify addiction treatment and public health strategies
tailored for cocaine injectors. Currently, there is no
standard pharmacotherapy proven effective for cocaine
addiction, though multiple therapeutic agents, including
anticonvulsants and stimulants have been investigated as
potential treatments [38,39]. A recent comprehensive re-
view of human clinical trials for potential novel therapies
for treatment of cocaine dependence outlined burgeon-
ing research in this field. It identified multiple promising
pharmocotherapies including dopamine agonists, seroto-
nergic agents and GABA-ergic medications and a cocaine
vaccine. One promising randomized controlled trial from
2013 demonstrated that topiramate was more efficacious
than placebo at reducing weekly cocaine use [40]. Add-
itionally, contingency management strategies have been
presented as possible interventions. One such study
showed that employment-based abstinence reinforce-
ment could lead to increased cocaine abstinence [41].
However, these strategies have been found to be challen-
ging to implement [38]. Future research should continue
to seek to identify a novel therapeutic intervention model
to reduce morbidity and mortality among cocaine injec-
tors in this setting.
A recent systematic review of mortality among PWIDs
found no significant differences in the risk of death by
type of primary drug injected [8]. The authors noted
some factors that reduced their capacity to detect such
differences, including a lack of adjustment for poly-
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that may not have been accounted for, and the fact that
HIV status was often imprecisely measured [8]. Another
systematic review of mortality among cocaine users
noted limited data on the extent of elevated mortality
among cocaine users [4]. They highlighted limitations of
previous studies, including the fact that many cohorts
were formed in drug treatment facilities with dependent
cocaine users who were at increased risk of premature
death and that the prevalence of HIV infection between
studies was highly variable [4]. Our study addressed
some of the limitations of previous studies by accounting
for poly-substance use, following up with participants
semi-annually to monitor ongoing drug use habits, and
testing for HIV infection at each visit. Furthermore, un-
like many previous studies, the present study population
was not selected from a drug treatment facility or com-
prised of cross-sectional examinations of deceased indi-
vidual’s toxicology reports.
There are several limitations in this study. Firstly, the
study sample is not a random sample, and therefore
generalizability of our findings may be limited. Secondly,
much of the data, particularly regarding drug use pat-
terns, were ascertained through self–reporting. There-
fore, our data may have been affected by reporting
biases including recall bias and socially desirable report-
ing. However, we note that this type of data has been
commonly utilized in observational studies involving
PWIDs and found to be valid [42,43]. Third, drug use
patterns directly before or at the time of death are not
described due to the method of self-reporting, which in-
hibits our ability to ascertain data as proximal to the
time of death. Fourth, although migration rates out of
the province have been shown to be low, mortality rates
may be underestimated, as participants who died outside
of BC were not included in the provincial registry. We
censored individuals with long durations (>12 months)
from behavioural measurement to death on the date of
last behavioural measurement. This may have resulted in
loss of precision regarding our risk factor measurement.
Fifth, for many variables, including alcohol use, we did not
have measures that considered refined patterns of use or
frequency of use and were often dichotomized into daily
versus less than daily use. Lastly, when the endpoint was
restricted to accidental mortality, daily cocaine injecting
did not remain significantly associated with the time to
accidental death, despite a trend towards an association.
This may reflect that accidental deaths, including acci-
dental poisonings, assault and accidental falls, are not ne-
cessarily predicted by specific drug use patterns. Future
research should seek to identify predictors of accidental
mortality among PWID. Finally, certain patterns of drug
use, such as intranasal cocaine use, are uncommon in this
sample and were not measured in our study.Conclusions
In summary, daily cocaine injecting was the only drug
use pattern independently associated with all-cause mor-
tality among a sample of PWIDs in Vancouver. These
findings highlight the need to identify novel effective
treatments and harm reduction strategies for cocaine
injectors.
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